The current status, challenges, and future developments of new tuberculosis vaccines
Mycobacterium tuberculosis complex causes tuberculosis (TB), one of the top 10 causes of death worldwide. TB results in more fatalities than multi-drug resistant (MDR) HIV strain related coinfection. Vaccines play a key role in the prevention and control of infectious diseases. Unfortunately, the on...
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
Taylor & Francis Group
2018-07-01
|
| coleção: | Human Vaccines & Immunotherapeutics |
| Assuntos: | |
| Acesso em linha: | http://dx.doi.org/10.1080/21645515.2018.1458806 |
| _version_ | 1827809758558552064 |
|---|---|
| author | Wenping Gong Yan Liang Xueqiong Wu |
| author_facet | Wenping Gong Yan Liang Xueqiong Wu |
| author_sort | Wenping Gong |
| collection | DOAJ |
| description | Mycobacterium tuberculosis complex causes tuberculosis (TB), one of the top 10 causes of death worldwide. TB results in more fatalities than multi-drug resistant (MDR) HIV strain related coinfection. Vaccines play a key role in the prevention and control of infectious diseases. Unfortunately, the only licensed preventive vaccine against TB, bacilli Calmette-Guérin (BCG), is ineffective for prevention of pulmonary TB in adults. Therefore, it is very important to develop novel vaccines for TB prevention and control. This literature review provides an overview of the innate and adaptive immune response during M. tuberculosis infection, and presents current developments and challenges to novel TB vaccines. A comprehensive understanding of vaccines in preclinical and clinical studies provides extensive insight for the development of safer and more efficient vaccines, and may inspire new ideas for TB prevention and treatment. |
| first_indexed | 2024-03-11T22:45:26Z |
| format | Article |
| id | doaj.art-0ef97453fe1c4aa1baa6c8f564f9bc13 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:45:26Z |
| publishDate | 2018-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-0ef97453fe1c4aa1baa6c8f564f9bc132023-09-22T08:38:21ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2018-07-011471697171610.1080/21645515.2018.14588061458806The current status, challenges, and future developments of new tuberculosis vaccinesWenping Gong0Yan Liang1Xueqiong Wu2Army Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute for Tuberculosis ResearchArmy Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute for Tuberculosis ResearchArmy Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute for Tuberculosis ResearchMycobacterium tuberculosis complex causes tuberculosis (TB), one of the top 10 causes of death worldwide. TB results in more fatalities than multi-drug resistant (MDR) HIV strain related coinfection. Vaccines play a key role in the prevention and control of infectious diseases. Unfortunately, the only licensed preventive vaccine against TB, bacilli Calmette-Guérin (BCG), is ineffective for prevention of pulmonary TB in adults. Therefore, it is very important to develop novel vaccines for TB prevention and control. This literature review provides an overview of the innate and adaptive immune response during M. tuberculosis infection, and presents current developments and challenges to novel TB vaccines. A comprehensive understanding of vaccines in preclinical and clinical studies provides extensive insight for the development of safer and more efficient vaccines, and may inspire new ideas for TB prevention and treatment.http://dx.doi.org/10.1080/21645515.2018.1458806bcgclinical trialsimmunologymycobacterium tuberculosistuberculosisvaccines |
| spellingShingle | Wenping Gong Yan Liang Xueqiong Wu The current status, challenges, and future developments of new tuberculosis vaccines Human Vaccines & Immunotherapeutics bcg clinical trials immunology mycobacterium tuberculosis tuberculosis vaccines |
| title | The current status, challenges, and future developments of new tuberculosis vaccines |
| title_full | The current status, challenges, and future developments of new tuberculosis vaccines |
| title_fullStr | The current status, challenges, and future developments of new tuberculosis vaccines |
| title_full_unstemmed | The current status, challenges, and future developments of new tuberculosis vaccines |
| title_short | The current status, challenges, and future developments of new tuberculosis vaccines |
| title_sort | current status challenges and future developments of new tuberculosis vaccines |
| topic | bcg clinical trials immunology mycobacterium tuberculosis tuberculosis vaccines |
| url | http://dx.doi.org/10.1080/21645515.2018.1458806 |
| work_keys_str_mv | AT wenpinggong thecurrentstatuschallengesandfuturedevelopmentsofnewtuberculosisvaccines AT yanliang thecurrentstatuschallengesandfuturedevelopmentsofnewtuberculosisvaccines AT xueqiongwu thecurrentstatuschallengesandfuturedevelopmentsofnewtuberculosisvaccines AT wenpinggong currentstatuschallengesandfuturedevelopmentsofnewtuberculosisvaccines AT yanliang currentstatuschallengesandfuturedevelopmentsofnewtuberculosisvaccines AT xueqiongwu currentstatuschallengesandfuturedevelopmentsofnewtuberculosisvaccines |